AU2001276934A1 - Methods of modulating fibrosis - Google Patents

Methods of modulating fibrosis

Info

Publication number
AU2001276934A1
AU2001276934A1 AU2001276934A AU7693401A AU2001276934A1 AU 2001276934 A1 AU2001276934 A1 AU 2001276934A1 AU 2001276934 A AU2001276934 A AU 2001276934A AU 7693401 A AU7693401 A AU 7693401A AU 2001276934 A1 AU2001276934 A1 AU 2001276934A1
Authority
AU
Australia
Prior art keywords
methods
modulating fibrosis
fibrosis
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001276934A
Inventor
George Liang King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Joslin Diabetes Center Inc
Original Assignee
Joslin Diabetes Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joslin Diabetes Center Inc filed Critical Joslin Diabetes Center Inc
Publication of AU2001276934A1 publication Critical patent/AU2001276934A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
AU2001276934A 2000-07-18 2001-07-17 Methods of modulating fibrosis Abandoned AU2001276934A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21924400P 2000-07-18 2000-07-18
US60219244 2000-07-18
PCT/US2001/022347 WO2002007747A1 (en) 2000-07-18 2001-07-17 Methods of modulating fibrosis

Publications (1)

Publication Number Publication Date
AU2001276934A1 true AU2001276934A1 (en) 2002-02-05

Family

ID=22818479

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001276934A Abandoned AU2001276934A1 (en) 2000-07-18 2001-07-17 Methods of modulating fibrosis

Country Status (4)

Country Link
US (1) US7175844B2 (en)
EP (1) EP1311277A4 (en)
AU (1) AU2001276934A1 (en)
WO (1) WO2002007747A1 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IL144144A0 (en) 1999-01-13 2002-05-23 Bayer Ag Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
EP2279757A3 (en) 2000-06-02 2011-08-03 Bracco Suisse SA Compounds for targeting endothelial cells
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
CA2417960C (en) 2000-08-04 2012-07-10 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
EP1386004A4 (en) 2001-04-05 2005-02-16 Ribozyme Pharm Inc Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
CA2526831C (en) * 2001-05-18 2012-07-31 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
ATE526041T1 (en) * 2001-12-11 2011-10-15 Fibrogen Inc METHOD FOR INHIBITING OCCULAR PROCESSES
PT1478358E (en) 2002-02-11 2013-09-11 Bayer Healthcare Llc Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7985402B2 (en) * 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US7261876B2 (en) * 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
AU2003278807A1 (en) * 2002-03-01 2004-08-13 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7666979B2 (en) * 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
WO2004075917A1 (en) * 2003-02-28 2004-09-10 Toudai Tlo, Ltd. Organ or tissue fibrosis inhibitor
HUE039154T2 (en) 2003-03-03 2018-12-28 Dyax Corp Peptides that specifically bind HGF receptor (cMet) and uses thereof
CN103191410B (en) 2003-05-15 2015-03-04 安皮奥制药股份有限公司 Treatment of T-cell mediated diseases
ATE366108T1 (en) 2003-05-20 2007-07-15 Bayer Pharmaceuticals Corp DIARYL UREAS FOR PDGFR-MEDIATED DISEASES
AU2005212433B2 (en) 2003-05-23 2010-12-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sINA)
PL1663978T3 (en) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
AU2005244154C1 (en) * 2004-04-28 2010-07-01 Fibrogen, Inc. Treatments for pancreatic cancer
MXPA06012394A (en) 2004-04-30 2007-01-31 Bayer Pharmaceuticals Corp Substituted pyrazolyl urea derivatives useful in the treatment of cancer.
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP1809364A4 (en) * 2004-11-12 2010-06-16 Univ Minnesota A veinous occlusion device and methods of using
US20060154939A1 (en) * 2004-12-24 2006-07-13 Boehringer Ingelheim International Gmbh Medicaments for the Treatment or Prevention of Fibrotic Diseases
US20070102622A1 (en) * 2005-07-01 2007-05-10 Olsen Richard I Apparatus for multiple camera devices and method of operating same
US8735178B2 (en) * 2006-03-27 2014-05-27 University Of Kentucky Research Foundation Withanolides, probes and binding targets and methods of use thereof
EP2121681B1 (en) 2007-01-11 2015-04-15 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
US8501789B2 (en) * 2007-01-19 2013-08-06 The Trustees Of The University Of Pennsylvania Use of salicylaldehyde isonicotinoyl hydrazone (SIH) for protection against retinal disease
EP2225226B1 (en) * 2007-12-26 2016-08-17 Critical Outcome Technologies, Inc. Compounds and their use in a method for treatment of cancer
AU2009207923A1 (en) * 2008-01-23 2009-07-30 Rigshospitalet Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker YKL-40
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
AU2009293658A1 (en) 2008-09-22 2010-03-25 James Cardia Reduced size self-delivering RNAi compounds
EP2550001B1 (en) 2010-03-24 2019-05-22 Phio Pharmaceuticals Corp. Rna interference in ocular indications
CN103108642B (en) 2010-03-24 2015-09-23 雷克西制药公司 RNA in skin and fibrotic conditions disturbs
EP2550000A4 (en) 2010-03-24 2014-03-26 Advirna Inc Reduced size self-delivering rnai compounds
EP3235818A3 (en) 2010-04-01 2018-03-14 Critical Outcome Technologies, Inc. Compounds for the treatment of hiv
WO2012033792A2 (en) 2010-09-07 2012-03-15 Dmi Acquisition Corp. Treatment of diseases
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
BR112014007675A2 (en) 2011-10-10 2017-04-18 Ampio Pharmaceuticals Inc degenerative joint disease treatment
MY172699A (en) 2011-10-10 2019-12-10 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
WO2013063413A1 (en) 2011-10-28 2013-05-02 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
JP6069356B2 (en) * 2012-01-05 2017-02-01 クラノテク・アクチボラグ Quinoline compounds that are anti-angiogenic integrin α5β1 inhibitors for use in the treatment of fibrosis or fibrosis related diseases
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
EP3104845A4 (en) * 2014-02-10 2017-09-27 Salk Institute for Biological Studies Increasing storage of vitamin a, vitamin d and/or lipids
RU2020136589A (en) 2014-08-18 2020-12-24 Ампио Фармасьютикалз, Инк. TREATMENT OF DEGENERATIVE JOINT DISEASES
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
CA3053392A1 (en) * 2017-02-28 2018-09-07 The Board Of Trustees Of The Leland Stanford Junior University Antifibrotic activity of cd47 blockade
TW202108606A (en) 2019-05-03 2021-03-01 新加坡商新加坡保健服務私人有限公司 Treatment and prevention of metabolic diseases
WO2021141733A1 (en) 2020-01-07 2021-07-15 The Procter & Gamble Company Method of modulating a fibrotic condition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK285035B6 (en) * 1992-10-28 2006-05-04 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6410322B1 (en) * 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US6734285B2 (en) * 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US6001622A (en) * 1995-12-21 1999-12-14 Sunnybrook Health Science Centre Integrin-linked kinase and its use
WO1997034920A1 (en) 1996-03-21 1997-09-25 Sugen, Inc. Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
ATE405651T1 (en) * 1998-03-17 2008-09-15 Genentech Inc POLYPEPTIDES HOMOLOGUE TO VEGF AND BMP1
US6100090A (en) 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
ATE485834T1 (en) * 1998-09-08 2010-11-15 Ford Henry Health System METHOD FOR DETECTING CONNECTIVE TISSUE GROWTH FACTOR FOR DIAGNOSING KIDNEY DISEASES

Also Published As

Publication number Publication date
EP1311277A4 (en) 2004-08-25
WO2002007747A1 (en) 2002-01-31
US20020086013A1 (en) 2002-07-04
US7175844B2 (en) 2007-02-13
EP1311277A1 (en) 2003-05-21

Similar Documents

Publication Publication Date Title
AU2001276934A1 (en) Methods of modulating fibrosis
AU3867400A (en) Methods of using bioelastomers
AU2001289085A1 (en) Antisense modulation of flip-c expression
AU2001277054A1 (en) Antisense modulation of lysophospholipase i expression
AU2001291019A1 (en) Method of modulating neovascularization
AU2001280599A1 (en) Compounds and methods
AU2001253418A1 (en) Compounds and methods
AU2001292864A1 (en) Methods and compositions for modulating angiogenesis
AU2002306918A1 (en) Methods of modulating angiogenesis
AU2001247600A1 (en) Methods of modulating hair growth
AU2001243394A1 (en) Compounds and methods
AU2001227847A1 (en) Antisense modulation of pepck-cytosolic expression
AUPQ872300A0 (en) Compounds and methods
AU2001280588A1 (en) Methods of modulating angiogenesis
AUPQ904100A0 (en) Method of encryption
AU2001278951A1 (en) Compounds and methods
AU2001284047A1 (en) Butinol I esterase
AU2001294823A1 (en) Hydrolases
AU2001275667A1 (en) Homocinetic joint
AU2002243429A1 (en) Antisense modulation of tnfr1 expression
AU2001288238A1 (en) Methods of modulating activity of dxr
AU2002235277A1 (en) Compounds and methods
AU2000274825A1 (en) Cosmetic method
AU2002245089A1 (en) Antisense modulation of cytohesin-1 expression
AU2001258330A1 (en) New uses of imidazolylmethyl-pyridines